Apellis Pharmaceuticals, Inc. $APLS Shares Bought by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. grew its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 30,747.3% during the 4th quarter, HoldingsChannel reports. The firm owned 185,392 shares of the company’s stock after buying an additional 184,791 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Apellis Pharmaceuticals were worth $4,657,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Apellis Pharmaceuticals by 207.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,559 shares of the company’s stock valued at $667,000 after buying an additional 19,944 shares during the period. Goldman Sachs Group Inc. raised its holdings in Apellis Pharmaceuticals by 26.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 307,709 shares of the company’s stock valued at $6,730,000 after buying an additional 64,742 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Apellis Pharmaceuticals by 4.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 222,634 shares of the company’s stock valued at $4,869,000 after buying an additional 9,747 shares during the period. Focus Partners Wealth raised its holdings in Apellis Pharmaceuticals by 118.4% in the 1st quarter. Focus Partners Wealth now owns 21,883 shares of the company’s stock valued at $479,000 after buying an additional 11,862 shares during the period. Finally, Acadian Asset Management LLC raised its holdings in Apellis Pharmaceuticals by 1,146.2% in the 1st quarter. Acadian Asset Management LLC now owns 23,976 shares of the company’s stock valued at $522,000 after buying an additional 22,052 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Analysts Set New Price Targets

APLS has been the topic of several research analyst reports. Royal Bank Of Canada reduced their price objective on shares of Apellis Pharmaceuticals from $22.00 to $21.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 25th. Wells Fargo & Company cut shares of Apellis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $26.00 to $41.00 in a report on Friday, April 17th. Wall Street Zen upgraded shares of Apellis Pharmaceuticals to a “hold” rating in a report on Saturday, May 16th. Citigroup reaffirmed a “neutral” rating and issued a $41.00 price target (down from $44.00) on shares of Apellis Pharmaceuticals in a report on Wednesday, April 1st. Finally, Mizuho upped their price target on Apellis Pharmaceuticals from $20.00 to $41.00 and gave the company a “neutral” rating in a report on Thursday, April 2nd. Three equities research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Apellis Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $35.72.

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS opened at $41.03 on Friday. The stock has a fifty day moving average price of $34.89 and a two-hundred day moving average price of $26.66. The stock has a market capitalization of $5.25 billion, a price-to-earnings ratio of 40.23 and a beta of -0.24. The company has a debt-to-equity ratio of 0.87, a quick ratio of 3.16 and a current ratio of 3.63. Apellis Pharmaceuticals, Inc. has a 1 year low of $16.10 and a 1 year high of $41.14.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.44. The firm had revenue of $268.30 million during the quarter, compared to analysts’ expectations of $208.91 million. Apellis Pharmaceuticals had a return on equity of 39.71% and a net margin of 12.06%. As a group, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.14 earnings per share for the current fiscal year.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.